Myriad Will Highlight New Data on Its myRisk(TM) Hereditary Cancer Test at the National Society of Genetic Counselors Annual ...
SALT LAKE CITY, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data on its myRisk™ Hereditary Cancer molecular diagnostic test will be featured in …